Patents by Inventor Travis R. Blum

Travis R. Blum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240287491
    Abstract: Aspects of the disclosure relate to Botulinum toxin X (BoNT X) protein variants (e.g., BoNT X protease variants). The variants provided herein have been evolved to cleave procaspase-1. Some of the variants provided herein do not cleave the native substrate of BoNT X protease, VAMP1 protein. Further aspects of the disclosure relate to nucleic acids encoding the procaspase-1 cleaving polypeptides described herein and expression vectors comprising the nucleic acids, as well as host cells and fusion proteins comprising the procaspase-1 cleaving polypeptides described herein and kits comprising the procaspase-1 cleaving polypeptides, nucleic acids, fusion proteins, expression vectors, or host cells described herein. Further aspects of the disclosure relate to methods of producing BoNT X protein variants (e.g., BoNT X protease variants) and methods of using the BoNT X protein variants (e.g., BoNT X protease variants), for example, to induce cell death.
    Type: Application
    Filed: May 3, 2024
    Publication date: August 29, 2024
    Applicants: The Broad Institute, Inc., President and Fellows of Harvard College
    Inventors: David R. Liu, Travis R. Blum, Julia McCreary
  • Patent number: 12060553
    Abstract: The disclosure provides amino acid sequence variants of Botulinum neurotoxin (BoNT) proteases that cleave (VAMP1, VAMP2, VAMP7, VAMP8, SNAP25, SNAP23, PTEN, etc.) and methods of evolving the same. In some embodiments, proteases described by the disclosure are useful for cleaving proteins found in a cell, that is in an intracellular environment. In some embodiments, proteases described by the disclosure are useful for treating diseases associated with increased or aberrant VAMP7, VAMP8, SNAP23 or PTEN expression or activity, for example, cancer and neurological disorders. Some aspects of this disclosure provide methods for generating BoNT protease variants by continuous directed evolution.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 13, 2024
    Assignees: President and Fellows of Harvard College, Ipsen Biopharm Ltd, The Broad Institute, Inc.
    Inventors: Michael S. Packer, Travis R. Blum, David R. Liu, Keith A. Foster, Matthew Brian Beard
  • Publication number: 20240052331
    Abstract: The disclosure provides fusion proteins comprising a pleckstrin homology (PH) domain and a variant of Botulinum neurotoxin E (BoNT E) protease that cleaves certain non-canonical protein targets (e.g., PTEN). Fusion proteins described in the disclosure are useful for cleaving target proteins found in a cell, that is, in an intracellular environment. Aspects of the disclosure provide methods for inhibiting PTEN amount, activity, or function in a cell or subject, the methods comprising administering to a call or subject a fusion protein described herein.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 15, 2024
    Applicants: The Board Institute, Inc., President and Fellows of Harvard College, Children's Medical Center Corporation
    Inventors: David R. Liu, Travis R. Blum, Min Dong, Hao Liu
  • Publication number: 20220259269
    Abstract: The disclosure provides amino acid sequence variants of Botulinum neurotoxin F (BoNT F) proteases that cleave SNARE proteins (e.g., VAMP1, VAMP7, etc.) and methods of evolving the same. In some embodiments, proteases described by the disclosure are useful for cleaving proteins found in a cell, that is in an intracellular environment. In some embodiments, proteases described by the disclosure are useful for treating diseases associated with increased or aberrant VAMP7 expression or activity, for example, cancer, transplantation rejection, graft-versus-host disease, and neurological disorders. Some aspects of this disclosure provide methods for generating BoNT protease variants by continuous directed evolution.
    Type: Application
    Filed: July 14, 2020
    Publication date: August 18, 2022
    Applicants: President and Fellows of Harvard College, The Broad Institute, Inc.
    Inventors: David R. Liu, Travis R. Blum
  • Publication number: 20210163924
    Abstract: The disclosure provides amino acid sequence variants of Botulinum neurotoxin (BoNT) proteases that cleave (VAMP1, VAMP2, VAMP7, VAMP8, SNAP25, SNAP23, PTEN, etc.) and methods of evolving the same. In some embodiments, proteases described by the disclosure are useful for cleaving proteins found in a cell, that is in an intracellular environment. In some embodiments, proteases described by the disclosure are useful for treating diseases associated with increased or aberrant VAMP7, VAMP8, SNAP23 or PTEN expression or activity, for example, cancer and neurological disorders. Some aspects of this disclosure provide methods for generating BoNT protease variants by continuous directed evolution.
    Type: Application
    Filed: August 27, 2018
    Publication date: June 3, 2021
    Applicants: President and Fellows of Harvard College, Ipsen Biopharm Ltd
    Inventors: Michael S. Packer, Travis R. Blum, David R. Liu, Keith A. Foster, Matthew Brian Beard